This meta-analysis, which included 8 randomized controlled trials and 2 non-randomized comparative studies involving 810 patients, showed that when all tumor types were pooled, ATR inhibitors did not significantly improve key efficacy outcomes compared with conventional therapies. Here, ATR is linked to neoplasm.